Skip to main content
. Author manuscript; available in PMC: 2022 Aug 11.
Published in final edited form as: Immunometabolism (Cobham). 2022 Jul 29;4(3):e00007. doi: 10.1097/IN9.0000000000000007

Figure 1.

Figure 1.

A schematic presentation of critical role of PERK in metabolic reprogramming of macrophages via epigenetic changes. (a) IL-4 stimulation to WT macrophages results in activation of immunosuppressive M2 macrophage via serine biosynthesis pathway (SBP). (b) IL-4 stimulation to PERKcKO macrophages or PSAT1cKO macrophages results in alteration in SBP, which is responsible to drive the immunosuppressive epigenetic modifications in M2 macrophages. (c) Treatment of mice with GSK2656157 (PERK inhibitor) or NCT-503 (PHGDH inhibitor) reduce tumor burden as a monotherapy and combination therapy of AntiPD1 + GSK2656157 potentiate the antitumor response.